Intragastric Balloon and Time-Restricted Eating for Weight Loss in Adults With Overweight or Obesity
Effects of Intragastric Balloon and Time-Restricted Intermittent Fasting Diet on Weight Loss and Metabolic Parameters in Adults With Overweight and Obesity
The goal of this non-randomized clinical study is to learn whether an intragastric balloon (IGB) and time-restricted eating (TRE; 16-hour daily fast with an 8-hour eating window), used alone or together, improve weight loss, body composition, and metabolic parameters in adults aged 18 to 65 years with overweight or obesity (body mass index 27.0 to 39.9 kg/m²). Participants are followed in four groups according to whether they have an IGB (placed as part of routine clinical care, not assigned by the study) and whether they choose to follow TRE: (1) standard nutrition therapy, (2) IGB plus standard nutrition therapy, (3) TRE plus standard nutrition therapy, and (4) IGB plus TRE plus standard nutrition therapy. All participants receive the same individualized energy-restricted diet, dietitian follow-up, behavioral education, and physical activity advice. Body weight and body composition are measured at baseline, 3 months, and 6 months; routine laboratory results are recorded at baseline and 6 months.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a prospective, single-center, non-randomized, exploratory (pilot) study with a 2×2 factorial structure. The two factors are intragastric balloon (IGB; present/absent) and time-restricted eating (TRE; yes/no). IGB placement is not a study procedure: it is performed as routine clinical care according to the physician's indication and the patient's preference, and the investigators have no role in that decision. TRE is offered in the dietetics outpatient clinic; participants who wish to follow it are allocated to the TRE groups, and those who do not are followed with standard nutrition therapy alone.
All groups receive the same frequency of dietitian visits, the same behavioral education, comparable energy targets, and the same physical activity advice (7,500 to 10,000 steps per day), so that groups differ only in IGB status and TRE. Body composition is measured by multi-frequency bioelectrical impedance analysis. Laboratory values are taken from routine clinical test results; no additional blood samples are drawn. Dietary intake is assessed with 3-day food records and physical activity with participants' smartphone step counters.
At least 15 participants per group (60 in total) are planned. Main and interaction effects of IGB and TRE will be analyzed with two-way analysis of variance or general linear models, and changes over time with repeated-measures analysis of variance or linear mixed models, adjusting for age, sex, baseline body mass index, comorbidities, physical activity, and energy intake.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Seher Şen, Assistant Professor
- Numéro de téléphone: 05393919700
- E-mail: seherdalli@gmail.com
Lieux d'étude
-
-
Yıldırım
-
Bursa, Yıldırım, Turquie (Türkiye)
- Recrutement
- Yıldırım Doruk Hastanesi
-
Contact:
- Yıldırım Doruk Hastanesi Seher ŞEN, Assistant Professor
- Numéro de téléphone: 05393919700
- E-mail: seher.sen@mudanya.edu.tr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18 to 65 years
- Body mass index (BMI) 27.0 to 39.9 kg/m²; for BMI 27.0 to 29.9 kg/m², at least one obesity-related comorbidity (e.g., insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia)
- BMI of 27 kg/m² or higher for at least 2 years
- History of unsuccessful non-surgical weight-loss attempts
- Willingness to participate and written informed consent
Exclusion Criteria:
- Inflammatory bowel disease or other inflammatory conditions of the gastrointestinal tract (including esophagitis and hiatal hernia of 2 cm or larger)
- Previous gastrointestinal surgery
- History of upper gastrointestinal bleeding
- Gastroparesis
- Severe psychiatric illness
- Active malignancy
- Pregnancy or breastfeeding
- Alcohol or substance dependence
- Physical limitation preventing exercise
- Contraindication to intragastric balloon placement
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard Nutrition Therapy
Participants without an intragastric balloon who receive standard energy-restricted nutrition therapy only. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. |
|
Comparateur actif: IGB + Standard Nutrition Therapy
Participants with an intragastric balloon (IGB) placed as part of routine clinical care who receive standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice. |
|
Expérimental: TRE + Standard Nutrition Therapy
Participants without an intragastric balloon who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks. |
|
Expérimental: IGB + TRE + Standard Nutrition Therapy
Participants with an intragastric balloon (IGB) placed as part of routine clinical care who follow time-restricted eating (TRE; 16-hour daily fast, 8-hour eating window) in addition to standard energy-restricted nutrition therapy. |
Individualized balanced diet with approximately 25% energy restriction from the estimated daily energy requirement (typically 1000 to 1400 kcal/day; protein 1.0 to 1.5 g/kg/day, carbohydrate 35 to 50% and fat 25 to 35% of energy), with regular dietitian follow-up, behavioral education, and advice to walk 7,500 to 10,000 steps per day. Endoscopically placed intragastric balloon, performed as part of routine clinical care based on physician indication and patient preference; placement is not assigned by the study. Diet after placement progresses through clear liquid, full liquid, pureed, and solid stages according to routine clinical practice. Daily food intake limited to an 8-hour eating window with a 16-hour fast. The recommended fasting period is 18:00 to 10:00; alternative 16-hour periods (such as 19:00 to 11:00 or 20:00 to 12:00) are allowed. Water and non-caloric beverages are permitted during the fasting period. Energy and macronutrient targets are identical to standard nutrition therapy. Duration: 6 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Body weight
Délai: Baseline, Month 3, Month 6
|
Kilograms, measured in light clothing without shoes (Tanita MC-780 MA) |
Baseline, Month 3, Month 6
|
|
Body mass index
Délai: Baseline, Month 3, Month 6
|
Weight and height combined to report BMI in kg/m² |
Baseline, Month 3, Month 6
|
|
Percent total weight loss
Délai: Month 3, Month 6
|
(Baseline weight - follow-up weight) / baseline weight × 100. |
Month 3, Month 6
|
|
Percent excess weight loss
Délai: Month 3, Month 6
|
(Baseline weight - follow-up weight) / (baseline weight - ideal weight) × 100; ideal weight at BMI 25 kg/m². |
Month 3, Month 6
|
|
Fat mass
Délai: Baseline, Month 3, Month 6
|
Kilograms, by multi-frequency bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Body fat percentage
Délai: Baseline, Month 3, Month 6
|
Percent of body weight, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Muscle mass percentage
Délai: Baseline, Month 3, Month 6
|
Percent of body weight, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
|
Muscle mass
Délai: Baseline, Month 3, Month 6
|
Kilograms, by bioelectrical impedance analysis |
Baseline, Month 3, Month 6
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting plasma glucose
Délai: Baseline, Month 6
|
Concentration in mg/dL from routine clinical laboratory results |
Baseline, Month 6
|
|
fasting insulin (µIU/mL)
Délai: Baseline, Month 6
|
Fasting serum insulin concentration in µIU/mL, obtained from routine clinical laboratory results. |
Baseline, Month 6
|
|
Glycated Hemoglobin (HbA1c)
Délai: Baseline, Month 6
|
Glycated hemoglobin (HbA1c) as a percentage of total hemoglobin, obtained from routine clinical laboratory results. |
Baseline, Month 6
|
|
Total Cholesterol
Délai: Baseline and Month 6
|
Serum total cholesterol concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
High-Density Lipoprotein (HDL) Cholesterol
Délai: Baseline and Month 6
|
Serum HDL cholesterol concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Triglycerides
Délai: Baseline and Month 6
|
Serum triglyceride concentration in mg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Alanine Aminotransferase (ALT)
Délai: Baseline and Month 6
|
Serum ALT activity in U/L, obtained from routine clinical laboratory results |
Baseline and Month 6
|
|
Aspartate Aminotransferase (AST)
Délai: Baseline and Month 6
|
Serum AST activity in U/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Serum Iron
Délai: Baseline and Month 6
|
Serum iron concentration in µg/dL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Ferritin
Délai: Baseline and Month 6
|
Serum ferritin concentration in ng/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Vitamin B12
Délai: Baseline and Month 6
|
Serum vitamin B12 concentration in pg/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Folate
Délai: Baseline and Month 6
|
Serum folate concentration in ng/mL, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Sodium
Délai: Baseline and Month 6
|
Serum sodium concentration in mmol/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Potassium
Délai: Baseline and Month 6
|
Serum potassium concentration in mmol/L, obtained from routine clinical laboratory results. |
Baseline and Month 6
|
|
Daily energy intake
Délai: Baseline and Month 6
|
Mean daily energy intake in kcal/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Protein Intake
Délai: Baseline and Month 6
|
Mean daily protein intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Carbohydrate Intake
Délai: Baseline and Month 6
|
Mean daily carbohydrate intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Fat Intake
Délai: Baseline and Month 6
|
Mean daily fat intake in g/day, calculated from a 3-day food record. |
Baseline and Month 6
|
|
Daily Step Count
Délai: Baseline and Month 6
|
Mean number of steps per day, reported by participants from their smartphone step counter. |
Baseline and Month 6
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MUDU-SBE-SS-06
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
In accordance with the study protocol approved by the ethics committee and national data protection legislation (Law No. 6698 on the Protection of Personal Data), individual participant data will be accessible only to the research team and will not be shared with third parties. Aggregate results will be published in peer-reviewed journals.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .